Fluorine-18-Florbetapir - Genentech/Molecular Neuroimaging
Alternative Names: [18F]florbetapir; [18F]G02941054; [18F]GTP1; [18F]MNI-798; F-18-MNI-798; Fluorine 18 MNI-798Latest Information Update: 28 Aug 2023
At a glance
- Originator Genentech
- Developer Genentech; Molecular NeuroImaging
- Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Alzheimer's disease
Most Recent Events
- 16 Jul 2023 Pharmacodynamics data from preclinical trial in Alzheimer’s disease presented at the Alzheimer's Association International Conference (AAIC-2023)
- 27 Jun 2023 Genentech completes a phase I trial in Alzheimer's disease (Diagnosis) in USA (NCT04566003)
- 19 Jul 2022 Washington University School of Medicine in collaboration with Roche Pharma initiates a phase I trial in Alzheimer's disease (Diagnosis, In adults, In the elderly) in USA (NCT05464368)